Document is current
Any future updates will be listed below
-
Authors
Kommoss, Katharina S. https://orcid.org/0000-0003-2428-2658
Krishnarajah, Sinduya https://orcid.org/0000-0003-2348-1751
Bieler, Tabea https://orcid.org/0000-0003-3611-9305
Friebel, Ekaterina https://orcid.org/0000-0003-1419-2376
Rindlisbacher, Lukas
Ramadori, Pierluigi https://orcid.org/0000-0001-6581-9648
Häne, Philipp https://orcid.org/0009-0007-5197-3338
Kam, Shing
Müller, Florian
Prokosch, Sandra
Rothermel, Ulrike
Wu, Yunchen
Barletta, Francesca https://orcid.org/0009-0002-1396-2252
Czemmel, Stefan https://orcid.org/0000-0002-9490-286X
Nahnsen, Sven https://orcid.org/0000-0002-4375-0691
Helm, Dominic https://orcid.org/0000-0001-9321-2069
Schneider, Martin
Schäkel, Knut https://orcid.org/0000-0001-6344-7799
Enk, Alexander https://orcid.org/0000-0002-1816-421X
Becher, Burkhard https://orcid.org/0000-0002-1541-7867
Heikenwälder, Mathias https://orcid.org/0000-0002-3135-2274
- License Information
-
More Information
Article History
Received: 13 October 2024
Accepted: 27 October 2025
First Online: 5 December 2025
Competing interests
: K.S.K. discloses to have received travel grants by Almirall, Janssen and Eli Lilly. K.S. discloses that he was an advisor and/or received speakers’ honoraria and/or received grants and/or participated in clinical trials of the following companies: AbbVie, Almirall, Boehringer Ingelheim, Celgene, Eli Lilly, Galderma, Janssen-Cilag GmbH, LEO Pharma, Novartis, Pfizer and UCB. A.E. discloses speakers’ honoraria/travel grants for Janssen-Cilag GmbH, Abbvie, and Eli Lilly. The authors declare that these conflicts are not associated with this work. The other authors have no competing interests to declare.
